Clinuvel Pharmaceuticals Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	87.21	86.38	81.22	72.18	60	42.6
Other Revenue	9.1	8.63	6.96	6.14	5.72	5.72
Revenue	96.3	95.02	88.18	78.32	65.72	48.32
Revenue Growth (YoY)	5.80%	7.76%	12.58%	19.17%	36.02%	48.37%
Cost of Revenue	9.99	8.48	7.73	7.52	9.25	4.17
Gross Profit	86.32	86.54	80.45	70.8	56.47	44.15
Selling, General & Admin	32.28	30.22	22.84	15.65	13.03	11.57
Research & Development	7.95	7.4	2.35	1.27	1.23	0.55
Other Operating Expenses	-0.02	-0.02	-0.56	-0.02	-0.22	-
Operating Expenses	43.32	40.78	31.88	26.67	20.92	15.58
Operating Income	43	45.76	48.57	44.13	35.55	28.57
Interest Expense	-5.04	-4.46	-4.45	-3.19	-2.27	-1.62
Interest & Investment Income	10.07	9.43	7.32	3.91	0.44	-
Currency Exchange Gain (Loss)	-3.83	0.83	-0.76	0.74	0.6	-1.37
EBT Excluding Unusual Items	44.2	51.55	50.68	45.58	34.32	25.58
Other Unusual Items	-	-	-	-	-	0.13
Pretax Income	44.2	51.55	50.68	45.58	34.32	25.71
Income Tax Expense	11.66	15.38	15.04	14.97	13.44	0.98
Earnings From Continuing Operations	32.54	36.17	35.64	30.6	20.88	24.73
Net Income	32.54	36.17	35.64	30.6	20.88	24.73
Net Income to Common	32.54	36.17	35.64	30.6	20.88	24.73
Net Income Growth	-16.08%	1.50%	16.44%	46.58%	-15.57%	64.29%
Shares Outstanding (Basic)	50	50	50	49	49	49
Shares Outstanding (Diluted)	51	50	51	52	52	51
Shares Change (YoY)	0.37%	-1.27%	-1.52%	0.08%	1.26%	1.33%
EPS (Basic)	0.65	0.72	0.72	0.62	0.42	0.50
EPS (Diluted)	0.64	0.72	0.70	0.59	0.40	0.48
EPS Growth	-16.35%	2.86%	18.11%	46.65%	-16.74%	62.42%
Free Cash Flow	40.08	40.8	31.48	35.88	39.44	18.41
Free Cash Flow Per Share	0.79	0.81	0.62	0.69	0.76	0.36
Dividend Per Share	0.050	0.050	0.050	0.050	0.040	0.025
Dividend Growth	-	-	-	25.00%	60.00%	-
Gross Margin	89.63%	91.08%	91.23%	90.40%	85.92%	91.36%
Operating Margin	44.65%	48.16%	55.08%	56.34%	54.09%	59.12%
Profit Margin	33.79%	38.07%	40.41%	39.08%	31.77%	51.18%
Free Cash Flow Margin	41.62%	42.94%	35.70%	45.82%	60.01%	38.10%
EBITDA	43.68	46.54	49.32	44.52	35.97	29.07
EBITDA Margin	45.36%	48.98%	55.93%	56.85%	54.74%	60.16%
D&A For EBITDA	0.68	0.79	0.75	0.4	0.43	0.5
EBIT	43	45.76	48.57	44.13	35.55	28.57
EBIT Margin	44.65%	48.16%	55.08%	56.34%	54.09%	59.12%
Effective Tax Rate	26.38%	29.83%	29.68%	32.85%	39.17%	3.83%
Revenue as Reported	102.57	105.3	95.31	82.99	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.